Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
Stocks mentioned in the article
ChangeLast1st jan.
BANK OF AMERICA 0.41% 29.4 Delayed Quote.-0.81%
IMMUNOMEDICS, INC. 2.64% 24.09 Delayed Quote.45.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
06/15IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Other Events, Fin..
AQ
06/15Immunomedics Announces Closing of Public Offering of Common Stock
GL
06/13IMMUNOMEDICS : Announces Pricing of Public Offering of Common Stock
AQ
06/11Immunomedics Announces Proposed Public Offering of Common Stock
GL
06/05CLOVIS ONCOLOGY : and Immunomedics Announce Planned Clinical Collaboration to St..
AQ
06/04IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/04Immunomedics Provides Business Update at the ASCO 2018 Investor Event
GL
06/04IMMUNOMEDICS INC : Regulation FD Disclosure, Other Events, Financial Statements ..
AQ
06/04Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to S..
GL
06/03Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Hea..
GL
More news
News from SeekingAlpha
06/13IMMUNOMEDICS : Short Term Risk, Long Term Opportunity 
06/13ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed 
06/13Immunomedics prices public offering of common stock 
06/11After Hours Gainers / Losers (06/11/2018) 
06/11Immunomedics files for mixed shelf offering; shares down 6% after hours 
Financials ($)
Sales 2018 5,15 M
EBIT 2018 -128 M
Net income 2018 -175 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 763x
Capi. / Sales 2019 120x
Capitalization 3 928 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 34,0 $
Spread / Average Target 45%
EPS Revisions
Managers
NameTitle
Michael Pehl President & Chief Executive Officer
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
Robert Iannone Chief Medical Officer, Head-Research & Development
David M. Goldenberg Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.45.24%3 928
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836